Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated

Pfizer vs Vertex: A Decade of SG&A Expense Trends

__timestampPfizer Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 201414097000000305409000
Thursday, January 1, 201514809000000377080000
Friday, January 1, 201614837000000432829000
Sunday, January 1, 201714784000000496079000
Monday, January 1, 201814455000000557616000
Tuesday, January 1, 201914350000000658498000
Wednesday, January 1, 202011615000000770456000
Friday, January 1, 202112703000000840100000
Saturday, January 1, 202213677000000944700000
Sunday, January 1, 2023147710000001136600000
Monday, January 1, 2024147300000001464300000
Loading chart...

Infusing magic into the data realm

A Tale of Two Giants: Pfizer Inc. vs Vertex Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Over the past decade, Pfizer Inc. and Vertex Pharmaceuticals have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pfizer's SG&A costs have remained relatively stable, averaging around $14 billion annually, with a slight dip in 2020. In contrast, Vertex Pharmaceuticals has seen a significant rise, with expenses growing nearly fourfold from $305 million in 2014 to over $1.1 billion in 2023. This growth reflects Vertex's aggressive expansion and investment in innovation. While Pfizer's expenses are nearly 20 times higher than Vertex's, the latter's rapid increase highlights its emerging influence in the sector. This comparison offers a fascinating glimpse into the strategic priorities of these pharmaceutical titans.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025